dengu
viru
denv
reemerg
viru
constitut
largest
vectorborn
diseas
viru
million
case
report
everi
year
although
denv
infect
induc
lifelong
immun
virus
serotyp
subsequ
infect
heterolog
serotyp
caus
sever
form
diseas
dengu
haemorrhag
fever
dhf
dengu
shock
syndrom
dss
howev
neither
approv
vaccin
specif
drug
avail
treat
diseas
studi
previous
develop
human
monoclon
antibodi
humab
show
strong
moder
cross
neutral
activ
select
target
domain
ii
envelop
glycoprotein
understand
clarifi
recognit
properti
matur
mechan
compris
variablediversityjoin
vdj
recombin
variabl
heavi
vh
variabl
light
vl
chain
pair
variabl
junction
site
somat
hypermut
shm
antibodi
studi
compar
predecessor
germlin
sequenc
imgtvquest
databas
appli
analyz
isol
vh
vl
sequenc
confirm
correct
isol
vhvl
humab
transient
express
cell
three
clone
express
recombin
igg
rigg
show
bind
neutral
activ
hybridoma
data
obtain
studi
elucid
properti
humab
genet
modif
bind
epitop
aed
mosquito
tropic
subtrop
area
member
flaviviru
genu
flavivirida
famili
envelop
icosahedr
positivestrand
rna
virus
approxim
genom
translat
singl
polyprotein
cleav
three
structur
protein
capsid
c
premembranemembran
prmm
envelop
e
seven
nonstructur
protein
host
viral
proteas
compris
four
distinct
serotyp
viru
major
caus
morbid
tropic
subtrop
region
estim
million
infect
case
annual
around
world
howev
nowaday
neither
proven
vaccin
specif
antivir
drug
serotyp
avail
infect
denv
caus
spectrum
clinic
symptom
rang
flulik
ill
dengu
fever
df
sever
fatal
diseas
known
dhf
dss
fatal
form
often
attribut
reinfect
heterolog
serotyp
primari
infect
four
serotyp
produc
lifelong
immun
serotyp
temporari
immun
other
moreov
sequenti
infect
presenc
heterolog
dengu
antibodi
often
lead
sever
secondari
infect
dhfdss
attribut
antibodydepend
enhanc
ade
nonneutr
antibodi
form
complex
viru
infect
phagocyt
via
fc
receptor
caus
viral
load
enhanc
infect
involv
dhfdss
http
passiv
antibodi
therapi
base
targetedspecif
monoclon
antibodi
mab
wide
studi
sever
infecti
diseas
includ
viral
diseas
cytomegaloviru
cmv
respiratori
syncyti
viru
rsv
hepat
b
viru
hbv
hepat
c
viru
hcv
rabi
vaccinia
varicellazost
viru
vzv
west
nile
viru
wnv
approv
use
prophylaxi
treatment
us
market
howev
therapeut
antibodi
treat
dengu
viru
still
limit
sever
studi
mous
human
antibodi
denv
impli
antibodi
target
envelop
protein
denv
ed
princip
determin
viru
neutral
ed
compos
domain
di
dii
diii
dii
locat
one
end
molecul
cover
fusion
peptid
respons
host
cellvir
fusion
end
locat
diii
involv
host
cell
bind
diii
diii
studi
target
sever
mous
human
antibodi
even
though
mous
mab
normal
show
strong
neutral
activ
serotyp
specif
dengu
viru
target
ediii
human
mab
humab
usual
show
divers
antibodi
respons
serotypeor
cross
reactiv
weak
strong
neutral
activ
sever
target
epitop
diii
diii
e
protein
similar
antidenv
humab
igg
iga
previous
gener
use
hybridoma
techniqu
show
strong
moder
crossneutr
activ
serotyp
dengu
viru
test
vitro
target
envelop
protein
denv
moreov
thirteen
character
found
target
domain
ii
e
protein
use
truncat
e
protein
epitop
map
studi
vaccin
design
genet
analysi
variabl
region
sequenc
antivir
ab
recent
shown
potenti
vaccin
develop
germlin
character
recent
wide
studi
sever
antivir
mab
includ
viru
influenza
viru
sar
coronaviru
hendra
viru
nipah
viru
use
phage
display
highthroughput
sequenc
one
studi
antiinfluenza
antibodi
shown
mutat
amino
acid
heavi
chain
complementari
determin
region
framework
region
evolv
full
activ
neutral
appli
ration
design
epitopespecif
vaccin
induc
broadlyneutr
antibodi
antidenv
mab
character
one
studi
character
mous
mab
target
ediii
rais
serotyp
dengu
viru
neutral
serotyp
differ
efficaci
found
mutat
hotspot
greatli
affect
bind
activ
mab
howev
germlin
studi
antidenv
humab
still
limit
reason
character
genet
sequenc
hybridoma
igg
target
e
mostli
target
edii
show
strong
moder
neutral
activ
need
good
model
antibodi
genet
studi
enlighten
dengu
vaccin
develop
induct
crossneutr
activ
previous
gener
hybridoma
secret
humab
igg
crossneutr
activ
select
neutral
humab
nhumab
produc
acut
dengu
patient
secondarili
infect
dengu
viru
serotyp
ribonucl
acid
rna
isol
hybriboma
cell
use
trizol
reagent
invitrogen
usa
complementari
dna
cdna
synthes
isol
rna
use
templat
amplif
heavi
chain
hc
light
chain
lc
use
pair
primer
twelv
reaction
hc
reaction
lc
kappa
reaction
lc
lambda
perform
tabl
specif
product
hc
lc
purifi
clone
pgemt
easi
vector
promega
usa
sequenc
isol
hclc
antibodi
gene
cover
entir
antibodi
variabl
domain
cdr
fr
character
imgt
uniqu
number
system
enter
immunogenet
imgt
vquest
databas
local
cdr
fr
includ
variat
mutat
origin
germlin
sequenc
analyz
vh
vl
fragment
amplifi
pgemteasi
vector
primer
contain
extend
restrict
site
amplifi
vh
vl
well
human
antibodi
constant
regioncontain
pqcx
plasmid
digest
noti
xhoi
restrict
enzym
vh
fragment
clone
pqcxipch
contain
hc
constant
region
similarli
vl
fragment
clone
either
pqcxihckappa
clambda
contain
constant
kappa
lambda
lc
respect
recombin
dna
transform
compet
cell
plasmid
amplifi
posit
clone
use
purelink
plasmid
midiprep
kit
invitrogen
usa
human
embryon
kidney
hek
cell
cultur
dmem
medium
supplement
fetal
bovin
serum
fb
without
sodium
pyruv
gibco
usa
cell
seed
cm
cell
cultur
dish
cellml
incub
co
overnight
next
day
twelv
microgram
pqcxihclvkappa
vlambda
dilut
optimem
reduc
serum
gibco
usa
ml
dilut
lipofectamin
ad
tube
contain
dilut
dna
gentli
mix
complex
incub
room
temperatur
min
ml
lipofectaminedna
complex
ad
cell
incub
co
h
incub
medium
replac
fresh
ml
cultur
medium
incub
co
day
presenc
igg
bind
activ
check
immunofluorescens
assay
ifa
use
transfect
cultur
medium
collect
cultur
fluid
transfect
cell
filter
purif
use
hitrap
protein
affin
column
ge
bioscienc
sweden
concentr
purifi
igg
measur
use
bca
protein
assay
kit
pierc
thermo
scientif
usa
vero
cell
monolay
micropl
mockinfect
infect
denv
serotyp
separ
incub
day
cell
fix
formaldehyd
phosphat
buffer
salin
pb
permeabil
triton
pb
cell
stain
hybridoma
humab
rigg
overnight
use
antiflaviviru
humab
posit
control
bound
antibodi
react
alexafluor
antihuman
igg
invitrogen
observ
fluoresc
microscop
neutral
test
perform
use
vero
cell
focu
number
firstli
adjust
obtain
approxim
focuseswel
vero
cell
seed
well
plate
cellswel
twofold
serial
dilut
antibodi
prepar
well
round
bottom
plate
ad
adjust
focu
number
dengu
viru
serotyp
abviru
mixtur
incub
min
mixtur
ad
vero
cell
incub
h
gentli
tap
everi
min
one
hundr
overlaid
medium
mem
cmc
fb
ad
well
incub
day
dengu
viru
serotyp
day
serotyp
assay
perform
triplic
day
incub
cell
fix
formaldehyd
follow
triton
focu
number
immunostain
incub
antidenv
mab
assay
number
focu
count
compar
antibodi
control
calcul
nt
gener
gener
matur
b
cell
antibodi
product
main
mechan
includ
rearrang
v
j
segment
pair
differ
vh
vl
germlin
addit
delet
junction
site
encod
loop
involv
divers
increas
b
cell
stimul
target
antigen
induc
shm
hotspot
increas
affin
toward
foreign
antigen
four
genet
process
built
high
divers
variabl
region
antibodi
studi
genet
basi
antidenv
humab
variabl
sequenc
igg
isol
acut
dengu
patient
studi
deriv
blood
sampl
patient
secondarili
infect
dengu
viru
serotyp
within
one
week
onset
fever
hc
lc
igg
sequenc
start
human
igg
leader
peptid
constant
region
igg
hc
lc
variabl
region
submit
imgtvquest
local
fr
cdr
sequenc
product
ig
rearrang
sequenc
stop
codon
infram
junction
except
clone
aa
insert
variabl
region
heavi
light
chain
clone
submit
databas
dna
data
bank
japan
ddbj
compar
sequenc
germlin
databas
germlin
hc
germlin
lc
use
tabl
major
germlin
hc
wherea
major
germlin
lc
fig
b
highest
hc
germlin
use
antidenv
humab
interestingli
highest
percentag
hc
germlin
also
previous
report
antivir
mab
influenza
viru
hiv
sar
cov
hendra
nipah
viru
found
germlin
gene
usag
hc
lc
differ
among
two
librari
frequent
found
librari
construct
day
post
infect
pbmc
contrast
frequent
use
hc
germlin
librari
construct
month
pbmc
compar
studi
igg
gener
acut
patient
pbmc
secondari
dengu
infect
suggest
primari
infect
high
frequenc
heavi
chain
germlin
presenc
igm
repertoir
major
group
germlin
heavi
chain
respons
antibodi
product
recoveri
human
immun
respons
stay
long
human
blood
circul
reinfect
occur
memori
b
cell
stimul
therefor
high
possibl
antibodi
product
kind
germlin
heavi
chain
observ
differ
combin
vhvl
gener
high
divers
antidenv
humab
variabl
also
found
junction
site
length
found
variabl
occur
humab
rang
aa
tabl
rang
aa
data
shown
high
divers
also
observ
antibodi
rang
aa
consid
determin
vh
divers
antibodi
repertoir
matur
b
cell
face
dengu
viru
antigen
divers
enhanc
shm
observ
mutat
throughout
variabl
region
differ
degre
variat
vh
less
variat
vl
among
igg
three
major
group
classifi
type
germlin
hc
kind
hc
germlin
combin
kind
germlin
lc
share
humab
humab
uniqu
hc
germlin
shown
tabl
align
humab
hc
group
along
closest
germlin
sequenc
includ
germlin
lc
well
annot
fr
cdr
shown
tabl
notic
among
humab
gr
use
hc
germlin
use
differ
germlin
lc
tabl
howev
humab
show
highest
nt
lgml
compar
nt
rang
lgml
impli
tabl
amino
acid
sequenc
heavi
chain
major
group
classifi
type
heavi
chain
germlin
humab
align
predecessor
germlin
includ
type
germlin
light
chain
nt
cdr
fr
locat
accord
immunogenet
annot
somat
mutat
vh
humab
highlight
gray
color
combin
differ
hc
lc
greatli
affect
bind
antibodi
target
antigen
pair
less
match
contrari
gr
compos
humab
humab
use
hc
lc
germlin
differ
level
mutat
found
use
origin
germlin
hypermut
also
affect
nt
tabl
among
humab
humab
show
level
mutat
vh
vl
respect
show
nt
contrast
humab
less
variat
compar
germlin
counterpart
vh
vl
show
almost
time
higher
nt
concentr
tabl
howev
less
variat
germlin
sequenc
suggest
germlinelik
antibodi
low
level
shm
show
rel
high
bind
target
antigen
phenomenon
also
previous
evidenc
chen
et
al
support
antibodi
minim
mutat
bind
viru
caus
acut
infect
like
sar
cov
hendra
viru
rel
high
affin
chronic
diseas
like
moreov
detail
character
humab
show
highest
activ
bind
neutral
activ
previous
describ
select
notic
clone
show
highest
variat
henc
suggest
mechan
gener
play
role
increas
bind
affin
one
antibodi
toward
target
antigen
studi
function
isol
vh
vl
best
humab
select
product
rigg
subclon
variabl
region
hc
lc
anoth
mammalian
express
plasmid
contain
either
constant
hc
constant
lc
kappa
lambda
construct
plasmid
cotransfect
human
embryon
kidney
hek
cell
rigg
express
test
bind
neutral
activ
three
clone
bind
serotyp
dengu
viru
infect
vero
cell
manner
igg
secret
hybridoma
cell
fig
moreov
three
also
show
almost
neutral
activ
hybridoma
fig
confirm
right
combin
vhvl
monoclon
antibodi
use
construct
plasmid
differ
combin
vh
vl
construct
humab
test
total
combin
includ
origin
vhvl
pair
found
correct
combin
three
clone
show
optim
bind
activ
ifa
impli
cdr
loop
region
much
respons
antigen
bind
three
clone
need
correct
combin
vh
vl
conform
form
antigen
bind
site
understand
affin
pathway
mani
humab
variou
activ
exampl
low
moder
high
nt
titer
need
identif
critic
posit
hotspot
like
major
impact
antibodi
activ
affin
